Masuda, Norikazu
Mukai, Hirofumi
Inoue, Kenichi
Rai, Yoshiaki
Ohno, Shinji
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Umeyama, Yoshiko
Iwata, Hiroji
Toi, Masakuzu
Clinical trials referenced in this document:
Documents that mention this clinical trial
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
https://doi.org/10.1200/jco.23.00137
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
https://doi.org/10.1007/s12282-019-00970-7
Documents that mention this clinical trial
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
https://doi.org/10.1007/s12282-019-00970-7
Documents that mention this clinical trial
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
https://doi.org/10.1007/s12282-019-00970-7
Funding for this research was provided by:
Pfizer Inc.
Article History
Received: 16 December 2018
Accepted: 16 March 2019
First Online: 24 May 2019
Change Date: 5 June 2019
Change Type: Correction
Change Details: The correct name of the last author should be “Masakazu Toi”, and not ‘‘Masakuzu Toi” as given in the original publication of the article.
Compliance with ethical standards
:
: N. Masuda has received honoraria from Chugai, AstraZeneca, Pfizer, and Takeda and has received research funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli Lilly, and Daiichi Sankyo. H. Iwata has received honoraria and research funding from Pfizer and AstraZeneca and fees for promotional materials from AstraZeneca. H. Mukai and Y. Rai have no conflicts of interest to report. K. Inoue has received research funding from Parexel, Puma Biotechnology, MSD, Novartis, GlaxoSmithKline, Pfizer, Chugai, and Daiichi Sankyo (institutional). S. Ohno has received honoraria from Chugai, AstraZeneca, Pfizer, Novartis, Taiho, Eisai, Kyowa-Hakko Kirin. M. Toi has received honoraria from Novartis, MSD, Takeda, AstraZeneca, Taiho, Chugai, Pfizer, Eisai, Eli Lilly, Kyowa-Hakko Kirin, and Genomic Health Institute; research funding from Novartis, AstraZeneca, Taiho, Chugai, Pfizer, and Eli Lilly; served as a consultant/independent contractor for Kyowa-Hakko Kirin and on an advisory board for Genomic Health Institute. S. Hashigaki and Y. Muramatsu are employees of Pfizer. Y. Mori and Y. Umeyama are employees of and stockholders in Pfizer.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.